Daily spirometry in an acute exacerbation of adult cystic fibrosis patients

Michael J Stephen1, Alex Long2, Chad Bonsall3, Jeffrey B Hoag1, Smita Shah4, Dorothy Bisberg4, Douglas Holsclaw3, Laurie Varlotta5, Stan Fiel6, Doantrang Du7, Robert Zanni7 and Denis Hadjiliadis3

Abstract
To help answer the question of length of intravenous antibiotics during an acute exacerbation of cystic fibrosis (CF), we had subjects to follow daily home spirometry while on intravenous antibiotics. CF patients, 18 and older, with an acute exacerbation requiring intravenous antibiotics had a daily FEV1. The average time to a 10% increase over their initial sick FEV1 was calculated, as well as the time to a new baseline. A total of 25 subjects completed the study. Ten of the 25 subjects did not have a sustainable 10% increase in FEV1. Of the 15 subjects with a sustainable 10% increase in FEV1, it took 5.2 days (±4.5) after day 1, while a new baseline was achieved on average at 6.6 days (±4.8) after day 1. Given the wide range of time to a 10% improvement and new baseline, it is recommended there should be flexibility in length of intravenous antibiotics in CF, not by a preset number.

Keywords
Cystic fibrosis, acute exacerbation, home spirometry, CFQ-R, intravenous antibiotics

Date received: 29 September 2016; accepted: 18 October 2017

Introduction
Acute exacerbations in cystic fibrosis (CF) are a leading cause of morbidity and mortality. An acute exacerbation in two separate studies was negatively correlated with 2- and 5-year survival rates.1,2 Acute exacerbations are also associated with lower lung function later in life, increased health-care costs, and decreased quality of life.3–5 Many subjects also fail to get back to their pre-exacerbation baseline for spirometry.6,7 Episodes of acute exacerbation affect not only the lungs but also psychological well-being.8,9 Exacerbations also occur more frequently with increasing age and declining lung function, creating a downward cycle as subjects get sicker.10

The underlying causes for an acute exacerbation are not well described, and although guidelines exist, there is no universally agreed upon standardized treatment regimen. Randomized trials demonstrating the efficacy of intravenous antibiotics have been small but have shown an improvement in the bacterial...
load in the airways, as well as an improvement in the FEV1 and symptoms.11,12

Despite their widespread use, the optimal length of intravenous therapy is unclear. A recent Cochrane review, as well as the 2009 CF foundation guidelines on the treatment of an acute exacerbation, identified no trials that would be helpful to answer this question.13,14 Several observational studies using spirometry have yielded conflicting results, with some advocating shorter courses of antibiotics than the standard 14 days, and others for an individualized approach.15–17

Pulmonary function testing is one surrogate marker to follow lung improvement to inform us when the benefits of intravenous antibiotics occur and also potentially when they could be stopped. FEV1 is an outcome measure followed commonly in clinical trials for medication efficacy and has correlated with mortality in CF.18,19 In an effort to understand the effects of intravenous antibiotics, we undertook a prospective observational cohort study of daily spirometry in CF subjects, 18 and older, during an acute exacerbation.

### Materials and methods

#### Study design

CF subjects who were deemed by their physician to have a severe acute exacerbation requiring intravenous antibiotics were eligible for participation. Baseline characteristics were collected, and subjects were given a handheld home spirometer along with instructions for usage (PiKo-6®; nSpire Health, Inc., Longmont, Colorado USA). Subjects were asked to check their FEV1 every morning after airway clearance. They performed daily spirometry during the time they were on intravenous antibiotics. This data were not used by clinicians to tailor antibiotic length. Baseline characteristics were collected as summarized in Table 1, including their baseline FEV1 based on a prior well visit in the last 6 months before their acute exacerbation. Each patient also completed a CF Questionnaire-Revised (CFQ-R) at day 1 and weekly during their exacerbation. Institutional Review Board approval was obtained at all participating sites prior to enrollment.

#### Sample

Patients, 18 and over, from six centers from the Mid-Atlantic region recruited subjects for the study: Drexel University adult, University of Pennsylvania adult, Morristown Medical Center adult, Monmouth Medical Center adult and pediatrics, St Christopher’s Hospital for Children pediatrics, and Barnabas Health pediatrics. The Drexel University Adult center served as the lead center for data collection and analysis. Subjects were enrolled between January 1, 2013 and August 1, 2015.

#### End points and statistical analysis

Two primary end points were followed on each patient. The first was the time it took to achieve a sustainable increase in the FEV1. To calculate this, an initial sick baseline was first documented, which was defined as the FEV1 on the first day of the exacerbation. The time it took to achieve a sustainable increase over their initial sick baseline was defined as the first day of three consecutive days where the FEV1 increased by at least 10% over their initial sick baseline.

The second calculation was the time it took to achieve a new baseline. The new baseline was defined as the average of the subjects’ final three values of their FEV1 while on intravenous antibiotics. The day on which the subject first got within 5% of this new

| Table 1. Baseline characteristics. a |
|--------------------------------------|
| Total \( (N = 25) \)                  |
| Age (years)                          | 28.9 ± 8.4 |
| Female, n (%)                        | 19 (76)    |
| Baseline BMI \((\text{kg/m}^2)\)      | 22.71 ± 6  |
| FEV1% predicted (baseline)           | 56 ± 19    |
| Diabetes at baseline, n (%)          | 6 (24)     |
| Pseudomonas aeruginosa, n (%)        | 22 (88)    |
| Methicillin-resistant Staphylococcus aureus, n (%) | 8 (32)    |
| Pancreatic insufficiency, n (%)      | 22 (88)    |
| Sweat test (mM)                      | 98.8 ± 24  |
| Genotype                             |            |
| DF508 homozygous, n (%)              | 10 (40)    |
| DF508 heterozygous, n (%)            | 11 (44)    |
| Other, n (%)                         | 4 (16)     |
| Length of intravenous antibiotics    | 18.2 ± 6.8 |
| Average percent days spent inpatient | 51 ± 34    |
| Use of inhaled antibiotics during exacerbation, n (%) | 7 (28)    |
| DNase usage, n (%)                   | 24 (96)    |
| Average number of intravenous antibiotics | 2.2 ± 0.57 |

BMI: body mass index; SD: standard deviation.

aAll data are mean ± SD unless specified to be count (%).
baseline was then determined. Subjects were then subdivided based on whether they reached 5\% of their baseline value only once during their treatment course or if once they achieved a value within 5\% of their new baseline, it was then sustained.

A logistic regression to estimate the effect that baseline percent FEV1 had on the probability that a subject had a sustainable increase in their FEV1 measurement, as defined above, was performed both with the subject’s baseline percent FEV1 as a continuous predictor and as a categorical variable with baseline percent FEV1 dichotomized as less than 50\% or greater than or equal to 50\%.

Finally, with regard to lung function, a ratio of the subject’s sick baseline on day 1 of their exacerbation was calculated to their prior well baseline. The prior well baseline was a value in the previous 6 months when the patient was known to be in good health. This was provided by the treating team based on chart review. The prior well baseline was also compared with the new baseline in a ratio to determine if subjects were able to get back to their prior lung function. A Wilcoxon Signed Rank Test was then performed to compare the sick baseline to the old baseline, as well as the new baseline.

**Results**

Baseline characteristic is summarized in Table 1. A total of 25 subjects were recruited into the study. The mean age was 28.9 years, and 76\% of the subjects were women. Ten subjects (40\%) were homozygous for delF508, and 11 (44\%) were heterozygous for delF508. The mean body mass index was 22.7. Pseudomonas colonization was present in 88\% of subjects, and the same percent were pancreatic insufficient. There were no *Burkholderia cepacia* subjects enrolled, whereas subjects with Methicillin-resistant *Staphylococcus aureus* constituted 32\% of the population. The average FEV1 was 56.2\% of predicted, suggesting a sicker than average adult cohort. The average length of intravenous antibiotics was 18 days.

Overall, 22 of the 25 subjects (88\%) had at least 1 day with a 10\% improvement over the course of their antibiotics. Of those 22 subjects, 15 (69\%) sustained this response. Of these 15 subjects, 14 of them never dipped below this 10\% cutoff again during their intravenous antibiotic course. One patient dropped temporarily below their 10\% cutoff but then increased over this threshold and sustained that increase. The remaining seven subjects did have a 10\% increase at some point in their intravenous antibiotic course, but this was not sustained over their final readings. Typical FEV1 graphs for those with a sustainable increase and those without a sustainable FEV1 increase are shown in Figures 1 and 2.

Of the 15 subjects who met criteria for a sustainable increase, it took an average of 5.2 days after day 1 to achieve this 10\% increase. This means that for the average patient, day 6 (rounded down from 6.2) was the first day where their FEV1 measurement was at least 10\% greater than the day 1 measurement. The standard deviation for this 10\% increase was 4.45 days.

The second primary end point was the time to a new baseline FEV1 while on intravenous antibiotics. For all 25 subjects, the average time to a new baseline was on day 6, with a standard deviation of 4.7 days. Of note, only 16 of these 25 patients maintained an FEV1 value within 5\% of their new baseline, once it was achieved through the rest of the course of their antibiotics. The other nine subjects achieved a value within 5\% of their final new
baseline but did not sustain it and dropped below this value again during the course of intravenous antibiotic before going up at the end to their new baseline. An example of one of these nine patients who did not sustain an FEV1 value within 5% of their final baseline is shown in Figure 3.

Those subjects who increased their FEV1 by at least 10% and sustained it were analyzed separately to see when they achieved their new baseline. For these 15 subjects, it took an average of 6.6 days after day 1 to get within 5% of their final baseline. The standard deviation to reach their new baseline was 4.8 days. This would put them at about day 8 when their new baseline was achieved, with a variation between day 3 and day 13.

When the prior well baseline FEV1 was used to see if it would influence whether the subject would have a sustainable increase in their FEV1, neither using FEV1% as a continuous predictor nor using it as a categorical predictor based on whether it was above or below 50% predicted yielded a significant result. The results from these two univariate models are found in Table 2.

The ratio of the new baseline to their prior well baseline was 0.96, indicating that average subjects did not get back to their prior well baseline. Within this analysis, 9 of 25 subjects (36%) exceeded their prior well baseline, while 16 of 25 (64%) did not achieve their prior well baseline. The standard deviation for the ratio of 0.96 was 0.14.

The ratio of their sick baseline, defined as their FEV1 on day 1, with their prior well baseline was 0.79, with all subjects having a ratio of less than 1. The standard deviation was 0.18.

The CFQ-R results for the analysis at the beginning and end of intravenous antibiotics are shown in Table 3. As seen, the CFQ-R was broken down into its respective categories. The four areas that showed a statistically significant change in the positive
direction from the beginning to end of antibiotics were health perceptions, respiratory, vitality, and physical function subscales. The other eight categories showed no difference.

**Discussion**

As stated, no adequate trials exist to definitively answer the question of length of IV antibiotics during an acute exacerbation of CF. Several observational trials have been undertaken to see if the following pulmonary function testing could help answer this question. The first of these was published by Redding et al., where 17 children had pulmonary function monitored every other day for 14 days of inpatient intravenous antibiotics. In this study, there was not a clear optimal length of antibiotics as there was variability in response times as reflected in pulmonary function. Similar results were seen in a retrospective study by Rosenberg and Schramm. In contrast, a retrospective study by Collaco et al. suggested that antibiotics could be potentially shortened as most improvements in FEV1 occur after 7–10 days of therapy.

The results for this study could be interpreted in several ways. The first would be to focus on the averages of FEV1 increase and time to sustainability. The two numbers to quote would be to expect a 10% increase at day 6, and that patients who increased their FEV1 would plateau at day 8. One would be tempted to cut down antibiotic lengths from 14 days based on this data.

This, however, would not tell the whole story. In those subjects who did sustain a 10% increase, the wide standard deviation of 4.45 days around the mean of 5.2 days would argue against using 5 or 6 days as a meaningful decision point. In looking at the time to a sustainable increase as a potential outcome measure to guide antibiotic length, similar issues arise. A significant portion of subjects, 36%, never reached a sustainable measurement of FEV1 within 5% of their ultimate baseline. This would argue that in an individual patient, FEV1 values fluctuated significantly during their course of intravenous antibiotics, too much to be able to draw conclusions about antibiotic length.

For those that did meet a sustainable threshold within 5% of their final new baseline, they did so on day 8 (mean), which would again appear to be a reasonable number to target. However, again the standard deviation of 4.8 days is so wide that it would be inadvisable to target treatment for all patients for a set length of time.

Using a patients’ baseline well lung function as a predictor for response to intravenous antibiotics also yielded disappointing results. There was also a wide range of presentations of initial sick FEV1 to the prior well baseline. Both of these results speak to the heterogeneity of the population being treated and the fact that it would seem imprudent to recommend similar lengths of antibiotics to this diverse population.

The results, however, are not entirely surprising and are in line with Redding et al. prospective study. CF subjects are colonized with a variety of different bacteria, all of which have variable sensitivities. Subjects with CF also present at different time courses in their exacerbations. There is also a wide range of underlying causes for exacerbations, with adherence to therapy, viral infections, dehydration, or other causes, all playing variable roles.

Given these data, it is our conclusion that the standard of care of 14 days for an acute exacerbation is reasonable, with flexibility for shorter or longer courses as clinically indicated. We know from Elborn et al. that treating subjects without symptoms at regular intervals yielded no difference in outcomes compared to those treated only for symptoms. A recent retrospective paper by Waters et al. also highlighted the heterogeneity to response to intravenous antibiotics and demonstrated that in a subset of subjects

### Table 3. CFQ-R before and after intravenous antibiotics.

| Section           | First CFQ-R scores | Last CFQ-R scores | p Value |
|-------------------|---------------------|-------------------|---------|
| Physical          | Mean 37.319 Median 33.333 | Mean 47.826 Median 41.667 | 0.028   |
| Vitality          | Mean 52.174 Median 50.000 | Mean 57.246 Median 58.333 | 0.040   |
| Emotion           | Mean 67.536 Median 66.667 | Mean 69.275 Median 73.333 | 0.678   |
| Eat               | Mean 80.193 Median 100.000 | Mean 84.541 Median 100.000 | 0.479   |
| Treatment burden  | Mean 36.232 Median 33.333 | Mean 35.749 Median 33.333 | 0.681   |
| Health perceptions| Mean 58.937 Median 55.556 | Mean 45.894 Median 44.444 | 0.010   |
| Social            | Mean 43.237 Median 44.444 | Mean 43.478 Median 44.444 | 1.000   |
| Body              | Mean 70.531 Median 66.667 | Mean 75.845 Median 77.778 | 0.114   |
| Role              | Mean 54.710 Median 58.333 | Mean 51.812 Median 50.000 | 0.252   |
| Weight            | Mean 72.464 Median 100.000 | Mean 79.710 Median 100.000 | 0.343   |
| Respiratory       | Mean 44.203 Median 38.889 | Mean 60.386 Median 66.667 | 0.009   |
| Digestion         | Mean 83.575 Median 88.889 | Mean 82.609 Median 88.889 | 0.722   |

CFQ-R: Cystic Fibrosis Questionnaire-Revised. *p Values bolded for significance.
continued improvement in lung function continued after 14 days.\textsuperscript{21}

This flexibility would help personalize care for these patients. Unfortunately, the main way to personalize treatment at the current time is based on clinical acumen and experience and not other objective measures. One tool that could help would be utilization of the CF Respiratory Symptom Diary-Chronic Respiratory Infection Symptom Scale (CFRSD-CRISS). In our results, the CFQ-R performed poorly from the beginning to the end of the exacerbation. However, data from the standardized treatment of pulmonary exacerbation study trial recently showed a correlation in the CFRSD-CRISS questionnaire with the beginning and end of intravenous antibiotic treatment.\textsuperscript{22} This could be a potential tool to aid practitioners considering stopping or continuing antibiotics.

There were limitations to the study. The total number of patients was small. It is possible that a bigger sample would yield significant correlations and predictions. It was also largely female. On the whole, however, the population was typical for a CF panel and spanned the typical spectrum of levels of illness seen in CF. In addition, treatment was not standardized across centers.

**Conclusion**

In summary, following daily FEV1 during an acute exacerbation can be helpful and give subjects a measure of speed of recovery. It did not, however, show a clear rate of increase and plateau in a cohort as a whole. Given this information, overall variation in treatment length is likely a good thing given the heterogeneity of the population and use of other treatment modalities during an exacerbation. FEV1 should be used in conjunction with clinical signs and symptoms to make a decision of when to start or stop intravenous antibiotics in an individual patient.

**Acknowledgements**

The authors would like to thank the authors of the CFQ-R, Alexandra Quittner PhD, Anne Buu PhD, Marc Watrous PhD, and Melissa A Davis MHS for allowing us to use their questionnaire.

**Declaration of conflicting interests**

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

**Funding**

The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This research was funded by the Medicine Department at Drexel University School of Medicine.

**References**

1. Mayer-Hamblett N, Rosenfeld M, Emerson J, et al. Developing cystic fibrosis lung transplant referral criteria using predictors of 2-year mortality. *Am J Respir Crit Care Med* 2002; 166: 1550–1555.
2. Liou TG, Adler FR, Fitzsimmons SC, et al. Predictive 5-year survivorship model of cystic fibrosis. *Am J Epidemiol* 2001; 152: 345–352.
3. De Boer K, Vandemheen KL, Tullis E, et al. Exacerbation frequency and clinical outcomes in adult patients with cystic fibrosis. *Thorax* 2011; 66: 680–685.
4. Lieu TA, Ray GT, Farmer G, et al. The cost of medical care for patients with cystic fibrosis in a health maintenance organization. *Pediatrics* 1999; 103: e72.
5. Hegarty M, Macdonald J, Watter P, et al. Quality of life in young people with cystic fibrosis: effects of hospitalization, age and gender, and differences in parent/child perceptions. *Child Care Health Dev* 2009; 35: 462–468.
6. Sanders DB, Hoffman LR, Emerson J, et al. Return of FEV1 after pulmonary exacerbation in children with cystic fibrosis. *Am J Respir Crit Care Med* 2010; 182: 127–134.
7. Sanders DB, Bittner RC, Rosenfeld M, et al. Pulmonary exacerbations are associated with subsequent FEV\textsubscript{1} decline in both adults and children with cystic fibrosis. *Pediatr Pulmonol* 2011; 46: 393–400.
8. Dobbin CJ, Bartlett D, Melehan K, et al. The effect of infective exacerbations on sleep and neurobehavioral function in cystic fibrosis. *Am J Respir Crit Care Med* 2005; 172: 99–104.
9. Britto MT, Kotagal UR, Hormung RW, et al. Impact of recent pulmonary exacerbations on quality of life in subjects with cystic fibrosis. *Chest* 2002; 121: 64–72.
10. Goss CH and Burn JL. Exacerbations in cystic fibrosis. 1: epidemiology and pathogenesis. *Thorax* 2007; 62: 360–367.
11. Regelmann WE, Elliott GR, Warwick WJ, et al. Reduction of sputum *Pseudomonas aeruginosa* density by antibiotics improves lung function in cystic fibrosis more than do bronchodilators and chest physiotherapy alone. *Am Rev Respir Dis* 1990; 141: 914–921.
12. Hyatt AC, Chippes BE, Kumor KM, et al. A double-blind controlled trial of anti-"Pseudomonas"
chemotherapy of acute respiratory exacerbations in subjects with cystic fibrosis. *J Pediatr* 1981; 99: 307–314.

13. Plummer A and Wilman M. Duration of intravenous antibiotic therapy in people with cystic fibrosis. *Cochrane Database Syst Rev* 2013; 31(5): CD006682. DOI: 10.1002/14651858.CD006682.pub4.

14. Flume PA, Mogayzel PJ Jr, Robinson KA, et al. Cystic fibrosis pulmonary guidelines: treatment of pulmonary exacerbations. *Am J Respir Crit Care Med* 2009; 180: 802–808.

15. Redding GJ, Restuccia R, Cotton EK, et al. Serial changes in pulmonary functions in children hospitalized with cystic fibrosis. *Am Rev Respir Dis* 1982; 12: 31–36.

16. Rosenberg SM and Schramm CM. Predictive value of pulmonary function testing during pulmonary exacerbations in cystic fibrosis. *Pediatr Pulmonol* 1993; 16: 227–235.

17. Collaco JM, Green DM, Cutting GR, et al. Location and duration of treatment of cystic fibrosis respiratory exacerbations do not affect outcomes. *Am J Resp Crit Care Med* 2010; 182: 1137–1143.

18. Ramsey BW, Dorkin HL, Eisenberg JD, et al. Efficacy of aerosolized tobramycin in subjects with cystic fibrosis. *N Engl J Med* 1993; 328: 1740–1746.

19. Kerem E, Reisman J, Corey M, et al. Prediction of mortality in patients with cystic fibrosis. *N Engl J Med* 1992; 326: 1187–1191.

20. Elborn JS, Prescott R, Stach BH, et al. Elective versus symptomatic antibiotic treatment in cystic fibrosis subjects with chronic Pseudomonas infection of the lungs. *Thorax* 2000; 55: 355–358.

21. Waters V, Stanojevic S, Sonneveld N, et al. Factors associated with response to treatment of pulmonary exacerbations in cystic fibrosis patients. *J Cyst Fibros* 2015; 14: 770–776.

22. Goss CH, Heltshe SL, Thompson V, et al. Standardized treatment of pulmonary exacerbation (STOP) study: Symptomatic treatment response. *J Cyst Fibr* 2015; 14: S106.